In vitro activities of nisin and nisin derivatives alone and in combination with antibiotics against Staphylococcus biofilms by Field, Des et al.
Title In vitro activities of nisin and nisin derivatives alone and in combination
with antibiotics against Staphylococcus biofilms
Author(s) Field, Des; O'Connor, Rory; Cotter, Paul D.; Ross, R. Paul; Hill, Colin
Publication date 2016-04-18
Original citation Field, D., O’ Connor, R., Cotter, P. D., Ross, R. P. and Hill, C. (2016) 'In
vitro activities of nisin and nisin derivatives alone and in combination
with antibiotics against Staphylococcus biofilms', Frontiers in
Microbiology, 7, 508 (11pp). doi: 10.3389/fmicb.2016.00508
Type of publication Article (peer-reviewed)
Link to publisher's
version
http://journal.frontiersin.org/article/10.3389/fmicb.2016.00508/full
http://dx.doi.org/10.3389/fmicb.2016.00508
Access to the full text of the published version may require a
subscription.
Rights © 2016, Field, O’ Connor, Cotter, Ross and Hill. This is an open-
access article distributed under the terms of the Creative Commons
Attribution License (CC BY). The use, distribution or reproduction
in other forums is permitted, provided the original author(s) or
licensor are credited and that the original publication in this journal
is cited, in accordance with accepted academic practice. No use,
distribution or reproduction is permitted which does not comply
with these terms.
https://creativecommons.org/licenses/by/4.0/
Item downloaded
from
http://hdl.handle.net/10468/4113
Downloaded on 2017-09-05T00:48:41Z
fmicb-07-00508 April 13, 2016 Time: 13:7 # 1
ORIGINAL RESEARCH
published: 18 April 2016
doi: 10.3389/fmicb.2016.00508
Edited by:
Marcelo Tolmasky,
California State University, Fullerton,
USA
Reviewed by:
Atte Von Wright,
University of Eastern Finland, Finland
Alfonso Jc Soler-Bistue,
Institut Pasteur, France
Taoufik Ghrairi,
University Tunis-ElManar, Tunisia
*Correspondence:
Des Field
des.field@ucc.ie;
Colin Hill
c.hill@ucc.ie
Specialty section:
This article was submitted to
Antimicrobials, Resistance and
Chemotherapy,
a section of the journal
Frontiers in Microbiology
Received: 08 February 2016
Accepted: 29 March 2016
Published: 18 April 2016
Citation:
Field D, O’ Connor R, Cotter PD,
Ross RP and Hill C (2016) In Vitro
Activities of Nisin and Nisin Derivatives
Alone and In Combination with
Antibiotics against Staphylococcus
Biofilms. Front. Microbiol. 7:508.
doi: 10.3389/fmicb.2016.00508
In Vitro Activities of Nisin and Nisin
Derivatives Alone and In
Combination with Antibiotics against
Staphylococcus Biofilms
Des Field1*, Rory O’ Connor1, Paul D. Cotter2,3, R. Paul Ross4 and Colin Hill1,3*
1 School of Microbiology, University College Cork, Cork, Ireland, 2 Teagasc Food Research Centre, Cork, Ireland, 3 APC
Microbiome Institute, University College Cork, Cork, Ireland, 4 College of Science, Engineering and Food Science, University
College Cork, Cork, Ireland
The development and spread of pathogenic bacteria that are resistant to the existing
catalog of antibiotics is a major public health threat. Biofilms are complex, sessile
communities of bacteria embedded in an organic polymer matrix which serve to further
enhance antimicrobial resistance. Consequently, novel compounds and innovative
methods are urgently required to arrest the proliferation of drug-resistant infections in
both nosocomial and community environments. Accordingly, it has been suggested
that antimicrobial peptides could be used as novel natural inhibitors that can be used
in formulations with synergistically acting antibiotics. Nisin is a member of the lantibiotic
family of antimicrobial peptides that exhibit potent antibacterial activity against many
Gram-positive bacteria. Recently we have used bioengineering strategies to enhance
the activity of nisin against several high profile targets, including multi-drug resistant
clinical pathogens such as methicillin-resistant Staphylococcus aureus, vancomycin-
resistant enterococci, staphylococci, and streptococci associated with bovine mastitis.
We have also identified nisin derivatives with an enhanced ability to impair biofilm
formation and to reduce the density of established biofilms of methicillin resistant
S. pseudintermedius. The present study was aimed at evaluating the potential of
nisin and nisin derivatives to increase the efficacy of conventional antibiotics and
to assess the possibility of killing and/or eradicating biofilm-associated cells of a
variety of staphylococcal targets. Growth curve-based comparisons established that
combinations of derivatives nisin V + penicillin or nisin I4V + chloramphenicol had
an enhanced inhibitory effect against S. aureus SA113 and S. pseudintermedius
DSM21284, respectively, compared to the equivalent nisin A + antibiotic combinations
or when each antimicrobial was administered alone. Furthermore, the metabolic activity
of established biofilms treated with nisin V + chloramphenicol and nisin I4V +
chloramphenicol combinations revealed a significant decrease in S. aureus SA113 and
S. pseudintermedius DSM21284 biofilm viability, respectively, compared to the nisin A +
antibiotic combinations as determined by the rapid colorimetric XTT assay. The results
indicate that the activities of the nisin derivative and antibiotic combinations represent a
significant improvement over that of the wild-type nisin and antibiotic combination and
merit further investigation with a view to their use as anti-biofilm agents.
Keywords: biofilm, bacterial resistance, antimicrobial peptide, nisin, lantibiotic, bacteriocin, staphylococci,
antibiotics
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INTRODUCTION
Staphylococcus aureus and S. pseudintermedius are major human
and/or animal pathogens. For humans, S. aureus is the leading
cause of bacteremia and infective endocarditis as well as
osteoarticular, skin and soft tissue, pleuropulmonary, and device-
related infections (Tong et al., 2015). It is also one of the main
aetiological agents of bovine mastitis, resulting in significant
economic losses to dairy enterprises (Viguier et al., 2009).
Worryingly, the horizontal transmission of methicillin resistance
to S. aureus in hospital and community settings, and the
growing prevalence of these strains, presents a significant
clinical challenge to the management of serious infections
worldwide (Stryjewski and Corey, 2014). S. pseudintermedius
has emerged over the last decade as a critically important,
opportunistic animal pathogen responsible for skin, soft tissue,
and surgical site infections (Ruscher et al., 2009; Murayama
et al., 2013) that also has implications for public health as
transmission between humans and animals has been described
(Paul et al., 2011). Critically, antibiotic resistance and the
ability to form biofilms (complex, sessile communities of
bacteria embedded in an organic polymer matrix (Flemming and
Wingender, 2010) contribute to the success of S. aureus and S.
pseudintermedius as pathogens in healthcare, community and
veterinary settings. Indeed, biofilm formation is now recognized
as an important virulence factor in several Staphylococcus sp.
(Otto, 2008), providing the bacteria with remarkable resistance
to diverse chemical, physical and biological antimicrobial
agents and is one of the main causes of persistent infection
(Archer et al., 2011). In addition to antibiotic resistance and
biofilm formation, the acquisition of other resistance genes
and resistance-facilitating mutations in some staphylococci
renders these strains impervious to many currently utilized
antimicrobial agents (Livermore, 2000; Chambers and Deleo,
2009). As only a handful of new antimicrobials have been
developed in the last decade, the further evolution of resistance
poses a serious threat to public health. Therefore, there is
an urgent need to identify new antimicrobial agents that
are not covered by existing mechanisms of resistance. The
development of anti-biofilm therapeutics has generally focused
on interfering with quorum sensing, inhibition of adhesion,
enhancement of dispersion, or bacteriophage-based treatments
(Mataraci and Dosler, 2012). Another potential strategy to reduce
biofilm-associated resistance is through synergistic effects of
antimicrobial agents in combination, which can enhance anti-
biofilm activities and help to prevent or delay the emergence
of resistance. One such group of compounds with immense
potential for therapeutic use is the lantibiotic class of bacteriocins
(bacterially derived antimicrobial peptides) (Cotter et al., 2005b,
2013). Lantibiotics are ribosomally synthesized peptides that
are defined by the presence of unusual amino acids including
lanthionine and/or methyllanthionine (Breukink and de Kruijff,
1999; Chatterjee et al., 2005; Bierbaum and Sahl, 2009). The
most meticulously researched lantibiotic is nisin. Produced by
Lactococcus lactis, nisin exhibits antibacterial activity against
a wide range of Gram-positive bacteria, including foodborne
pathogens such as staphylococci, bacilli and clostridia. Nisin
is used as a food preservative in over 50 countries and
has been approved in the EU and by the US Food and
Drug Administration (FDA; Delves-Broughton et al., 1996). In
addition, both nisin A (and its natural variant nisin Z) are
effective against the Gram-positive pathogens responsible for
bovine mastitis and have been incorporated into a number
of products devoted to restricting or treating such infections
(Sears et al., 1992; Wu et al., 2007). Notably, in addition to
being effective against planktonic cells of multi-drug resistant
staphylococci (Dosler and Gerceker, 2011; Okuda et al., 2013),
nisin has also demonstrated efficacy against biofilms (Corbin
et al., 2011; Dosler and Mataraci, 2013; Okuda et al., 2013).
Moreover, there is also a steadily growing number of engineered
nisin peptides that demonstrate enhanced functionalities (activity
and/or stability) which make them more attractive from a clinical
perspective (Cotter et al., 2013; Field et al., 2015a). Indeed, the
bioengineering of nisin has generated variants that exhibit not
only improved antimicrobial activity against strains of clinical
relevance (methicillin resistant S. aureus (MRSA), vancomycin-
resistant enterococci (VRE), vancomycin-intermediate S. aureus
(VISA), methicillin-resistant S. pseudintermedius (MRSP), and
C. difficile) but has also brought about the widening of its
antimicrobial spectrum (Field et al., 2008, 2012; Molloy et al.,
2013).
It has frequently been suggested that the efficacy of
individual lantibiotics could be further boosted through
combination with other antimicrobials or membrane-active
substances (Cavera et al., 2015a). Indeed, several studies have
demonstrated synergistic relationships between conventional
antibiotics and lantibiotics (Brumfitt et al., 2002; Cavera et al.,
2015b). For example, nisin displayed synergistic activity
with the antibiotics colistin and clarithromycin against
Pseudomonas aeruginosa (Giacometti et al., 2000), with
penicillin, streptomycin, chloramphenicol and rifampicin
against Pseudomonas fluorescens (Naghmouchi et al., 2012)
and with ramoplanin and other non-β-lactam antibiotics
against many strains of MRSA and VRE (Brumfitt et al., 2002).
Similarly, nisin-ceftriaxone and nisin-cefotaxime were found
to be highly synergistic against clinical isolates of Salmonella
enterica serovar Typhimurium as evident by checkerboard
and time-kill assays (Rishi et al., 2014). Notably, penicillin,
ciprofloxacin and chloramphenicol displayed greater potency
against biofilms of E. faecalis when used in combination with
nisin (Tong et al., 2014). We have previously described a novel
nisin variant with improved specific activity compared to nisin
A against strains of S. pseudintermedius that was also more
effective in preventing biofilm formation, and in reducing
the biofilm mass formed on microtiter plates (Field et al.,
2015b). With this in mind, this study set out to investigate
the ability of nisin and two enhanced nisin derivatives (nisin
I4V and nisin M21V) in conjunction with a selection of
currently utilized antibiotics to control a range of Staphylococcus
sp., including human and animal associated clinical isolates
with the ultimate aim of identifying superior anti-biofilm
combinations.
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MATERIALS AND METHODS
Bacterial Strains and Growth Conditions
Nisin and nisin derivative producing L. lactis strains (Table 1)
were grown in M17 broth supplemented with 0.5% glucose
(GM17) or GM17 agar at 30◦C. E. coli was grown in Luria-
Bertani broth with vigorous shaking or agar at 37◦C. A variety
of pathogenic staphylococcal targets were selected, including
two MRSA clinical isolates (ST528 and ST530), 3 strains
associated with animal infections (S. pseudintermedius DK729,
S. pseudintermedius DSM21284, S. intermedius DSM20373), 3
isolates associated with bovine mastitis (S. aureus DPC5243,
S. aureus DPC5347, S. aureus RF122) and a strain of S. aureus
(SA113) used as a representative staphylococcal organism in
model virulence studies (Kristian et al., 2003; Kneuper et al.,
2014; Table 1). S. pseudintermedius DK729, S. pseudintermedius
DSM21284 and S. intermedius DSM20373 have previously been
shown to form biofilms as determined by crystal violet staining
(Field et al., 2015b). S. aureus SA113 has also demonstrated ability
to form strong biofilms (Cramton et al., 1999). Staphylococcus
strains were grown in cation-adjusted Mueller Hinton (CA-MH)
(Oxoid) for minimum inhibitory concentration assays or Tryptic
Soy Broth (TSB) (Merck) supplemented with 1% Glucose at
37◦C for biofilm assays. Antibiotics were used where indicated at
the following concentrations: Chloramphenicol at 10 and 20 µg
ml−1, respectively, for L. lactis and E. coli.
Minimum Inhibitory Concentration
Assays
Minimum inhibitory concentration determinations were carried
out in triplicate in 96 well microtitre plates as described
previously (Field et al., 2010, 2012, 2015b). Briefly, target
strains were grown overnight in the appropriate conditions
and medium, subcultured into fresh broth and allowed to
grow to an OD600 of ∼0.5, diluted to a final concentration
of 105 cfu ml−1 in a volume of 0.2 ml. Chloramphenicol,
penicillin G, ampicillin, vancomycin, streptomycin, tetracycline,
erythromycin, ceftazidime, and cefuroxime (Sigma) were
resuspended in CA-MH media to a stock concentration of 128 or
256 µg/ml. The antibiotics were adjusted to 16, 32, or 64 µg/ml
starting concentration and twofold serial dilutions of each
compound were made in 96 well plates for a total of 12 dilutions.
The target strain was then added and after incubation for 16 h at
37◦C and the MIC was read as the lowest peptide concentration
causing inhibition of visible growth.
Nisin and Nisin Variant Purification
Nisin and nisin derivatives were purified according to previously
described protocols (Field et al., 2010; Molloy et al., 2013). Briefly,
2 l of Tryptone Yeast (TY) broth were incubated for 20 h with 1%
inoculum of an overnight culture of producing strain (nisin A,
nisin V, or nisin I4V). This culture was centrifuged for 20 min at
7000 rpm. The supernatant was decanted and passed through 60 g
of pre-equilibrated Amberlite XAD16 beads (Sigma–Aldrich).
The beads were washed with 500 ml 30% ethanol and eluted
with 500 ml 70% isopropanol (IPA) (Fisher) 0.1% trifluoroacetic
acid (TFA) (Sigma–Aldrich). Concomitantly, the cell pellets were
resuspended in 300 ml of 70% IPA 0.1%TFA and stirred at
room temperature for 3 hours followed by centrifugation. This
cell supernatant was combined with that referred to above and
concentrated through rotary-evaporation (Buchi, Switzerland)
to approximately 250 ml. Following pH adjustment to 4.0
further concentration was achieved through the use of a
Phenomenex SPE C-18 column to a final volume of 60 ml. 8 ml
of this sample was concentrated, through rotary evaporation,
to 2 ml and purified through HPLC using a Phenomenex C12
Reverse-Phase (RP) HPLC column (Jupiter 4 µ proteo 90 Å,
250 X 10.0 mm, 4 µm). To facilitate this, a gradient of 30–
50% acetonitrile (Fisher) containing 0.1% TFA was developed.
The relevant fractions were collected and pooled, subjected
TABLE 1 | Bacterial strains utilized in this study.
Strain Relevant characteristics Reference
L. lactis NZ9800 pDF05 L. lactis NZ9800 harboring pDF05 (plasmid pCI372 with nisA under its own
promoter). Wild type nisin A producer
Field et al., 2008
L. lactis NZ9800 pDF11 L. lactis NZ9800 harboring pDF11 (pCI372-nisA-M21V) Field et al., 2008
L. lactis NZ9800 pDF12 L. lactis NZ9800 harboring pDF12 (pCI372-nisA-I4V) Field et al., 2015b
S. aureus SA113 Representative staphylococcal organism in model virulence studies Kristian et al., 2003
S. aureus RF122 Represents the most common S. aureus clone derived from bovine mastitis
worldwide.
Fitzgerald et al., 1997
S. aureus DPC5243 Bovine mastitis-associated strain Fitzgerald et al., 1997
S. aureus DPC5247 Bovine mastitis-associated strain Fitzgerald et al., 1997
S. aureus ST528 (MRSA) Methicillin resistant S. aureus clinical isolate (BSAC)a Piper et al., 2009b
S. aureus ST534 (MRSA) Methicillin resistant S. aureus clinical isolate (BSAC)a Piper et al., 2009b
S. pseudintermedius DK729 UCC culture collection. Canine pathogen, biofilm former. Field et al., 2015b
S. pseudintermedius DSM21284 Type strain from lung tissue of cat.
Biofilm former
Devriese et al., 2005
S. intermedius DSM20373 Type strain from pigeon nares.
Biofilm former
Hájek, 1976
aBritish Society for Antimicrobial Chemotherapy.
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to rotary-evaporation to remove acetonitrile and freeze-dried
(LABCONCO). The purified peptides were subjected to MALDI-
ToF Mass Spectrometric analysis to confirm their purity before
use.
Growth Curve Experiments
For growth experiments, overnight cultures were transferred
(107 cfu ml−1 in a volume of 1.0 ml.) into CA-MH
supplemented with the relevant concentration of nisin wild-
type, nisin derivatives, and antibiotic/peptide combinations, and
subsequently 0.2 ml was transferred to 96 well microtitre plates
(Sarstedt). Cell growth was measured spectrophotometrically
over 24-h periods by using a SpectraMax M3 spectrophotometer
(Molecular Devices, Sunnyvale, CA, USA).
Biofilm Formation and Biofilm Treatment
With Purified Nisin A, Nisin Derivative,
and Antibiotic Combinations
Static microtitre plate assays based on a previous study
(Kelly et al., 2012), but with modifications to optimize the
assay, were used to investigate the biofilm formation and
nisin/antibiotic combination treatments. TSB (Merck) broth
supplemented with 1% D-(+)-glucose (Sigma Aldrich) (TSBg)
was used in these assays which aids in biofilm formation.
Briefly, a 1: 100 dilution was performed by adding 2 µl of
log phase cells (107 CFU ml−1 of each culture) to 198 µl of
TSBg in wells of a sterile 96-well microtitre plate (Sarstedt,
Leicester, UK), giving a starting inoculum of 105 CFU ml−1;
200 µl of TSBg was added to a set of wells as a negative
control. All wells were seeded in triplicate. Microtitre plates
were then incubated at 37◦C for 48 h to allow biofilm
formation to occur. After biofilms were established and washed
once with phosphate buffered saline (PBS), nisin peptides
were added to the microtitre plate wells at 1X, 2X, 4X,
8X, and 16X the relevant MIC as previously determined.
All wells were seeded in triplicate. Following incubation
for 24 h, at 37◦C, the plates were removed and gently
washed once with PBS, then 100 µL of a solution containing
500 mg XTT/L (2,3-bis[2-methyloxy-4-nitro-5-sulfophenyl]-2H-
tetrazolium-5-carboxanilide) (Sigma) and 10 mM menadione
(Sigma) was added to each well. Microtitre plates were incubated
for 2 h at 37◦C in the dark. Absorbance was measured at 490 nm
using a microtiter plate reader (Molecular Devices Spectramax
M3, Sunnyvale CA, USA). Data obtained in triplicate were
calculated and expressed as the mean± SD.
Confocal Microscopy
Biofilms of S. pseudintermedius DSM21284 were pre-formed
on µ-Plate 96 well uncoated microtitre plates (Ibidi, Germany)
suited to confocal microscopy applications. Following peptide
treatment, biofilms were rinsed once with PBS and stained by
using a Live/Dead BacLight viability kit (Molecular Probes).
100 ml of the solution containing SYTO 9 and propidium iodide
mixed in a ratio of 1:1 was added to the biofilm. The films
were incubated at room temperature for 15 min in the dark.
After incubation, residual stain was removed. The images were
observed using a Zeiss LSM 5 exciter confocal microscope with
a Plan-Apochromat 63x/1.40 Oil DIC M27 lens and images were
acquired using the Zen 2008 SP2 software. Sample were excited
using laser light at 488nm with emission light filtered with a
bandpass filter at 505–530 nm for Syto 9 and a longpass filter at
650 nm for propidium iodide (PI). Images were acquired using
two separate confocal channel (one for Syto 9 and one for PI) with
pinhole adjusted to 1 (confocal pinhole) at 1556× 1556 pixels.
RESULTS
MIC-Based Investigations of Antibiotics
MICs for a range of antibiotics, representing penicillins,
cephalosporins, glycopeptides, macrolides, aminoglycosides as
well as tetracycline, were carried out to establish suitable
concentrations for combinatorial studies with nisin and the
derivatives nisin V (M21V) and nisin I4V. The MIC was
determined to be the lowest concentration of antibiotic that
resulted in the absence of visible growth of the target strain
after 16 h at 37◦C in CA-MH. S. aureus SA113, DPC5243,
DPC5247, and RF122 proved to be susceptible to the majority of
the antibiotics utilized in the study (Table 2), with the exception
of ceftazidime (CZ). The MRSA isolate ST528 displayed high
MICs to erythromycin, chloramphenicol, ampicillin, ceftazidime
and cefuroxime (Table 2). In contrast, MRSA ST530 remained
sensitive to erythromycin and chloramphenicol.
Staphylococcus pseudintermedius DK729 and S. pseudinter-
medius DSM21284 both displayed a MIC of >16 µg/ml for
erythromycin, while S. pseudintermedius DK729 exhibited
MICs of 32, >32, and 8 µg/ml for ampicillin, ceftazidime and
cefuroxime, respectively (Table 2). S. intermedius DSM20373
remained sensitive to erythromycin, tetracycline, penicillin
and chloramphenicol but displayed high MIC values of
>32 µg/ml for both ceftazidime and cefuroxime. These
results highlight the multi-drug resistant nature of isolates of
S. intermedius and S. pseudintermedius. Indeed, methicillin
resistant S. pseudintermedius (MRSP) isolates have been
reported that are also typically resistant to aminoglycosides,
fluoroquinolones, macrolides, lincosamides, trimethoprim
sulfamethoxazol, and, in many cases, to tetracycline and
chloramphenicol (Yoo et al., 2010; Yoon et al., 2010).
Growth Curve-Based Comparisons of
the Activity of Nisin A, Nisin Derivatives,
and Antibiotic Combinations
Having established the MIC values for a range of antibiotics
against the representative staphylococci, growth curves were
performed in order to reveal more subtle features of the
impact of sub-lethal concentrations of nisin A, nisin V, and
nisin I4V alone, but also in combination with a selection of
antibiotics on bacterial growth. The final concentration of nisin
used for each organism was determined on the basis of MIC
results obtained previously against these indicator strains (Field
et al., 2010, 2015b). One microorganism was chosen from
each group to represent drug sensitive strains (SA113), animal
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TABLE 2 | Minimum inhibitory concentration results of a selection of antibiotics against representative staphylococcal targets.
Staphylococcus
Strain
Van
µg/ml
(>2)
Ery
µg/ml
(>2)
Tet
µg/ml
(>2)
PenG
µg/ml
Cm
µg/ml
(>8)
Strep
µg/ml
Amp
µg/ml
(>2)
CZ
µg/ml
(>4)
CF
µg/ml
(>4)
S. aureus SA113 0.488 0.25 0.125 0.0195 4 2.5 0.125 6.20 0.4
S. aureus RF122 0.976 0.488 1.0 > 10 2 5 3 16 2
S. aureus DPC5243 0.976 0.488 1 0.156 8 5 1 32 4
S. aureus DPC5247 0.976 0.488 1 0.156 8 80 2 32 4
MRSA
S. aureus ST528 0.625 >16 0.25 5 16 40 >64 >32 >32
S. aureus ST534 0.625 0.5 0.25 0.312 8 40 8 32 8
S. pseud/intermedius
S. pseudintermedius 1.95 >16 4 >10 4 80 32 >32 8
DK729
S. pseudintermedius 7.81 >16 >32 0.078 8 >80 0.125 16 0.5
DSM21284
S. intermedius 1.95 0.5 4 0.01 2 2.5 0.125 >32 >32
DSM20373
associated pathogens (S. pseudintermedius DSM21284) and drug-
resistant human clinical organisms (MRSA ST528). It was
decided that penicillin and chloramphenicol should be included
for combinatorial analysis given previous reports of synergism
between these antibiotics and nisin A (Lebel et al., 2013; Tong
et al., 2014). Indeed, in our studies, a slight increase in lag time
was evident when S. aureus SA113 was grown in the presence
of sub-lethal concentrations of nisin (0.937µM; 3.0 µg/ml) and
chloramphenicol (1.5 µg/ml) combined, compared to either
compounds used alone (Figure 1A). However, a greatly extended
lag time was evident in the case of the nisin derivative I4V +
chloramphenicol and nisin V + chloramphenicol combinations.
In contrast, when nisin and nisin derivatives were combined
with vancomycin (0.5µg/ml), no enhanced antimicrobial effect
was apparent since the combinations produced a shorter lag
time than when vancomycin was used alone (Figure 1B).
The nisin (0.937 µM; 3 µg/ml) and penicillin (0.005 µg/ml)
and nisin derivative/penicillin combinations had little to no
effect on the growth of SA113 at the concentrations used
(Figure 1C).
When S. pseudintermedius DSM 21284 was employed, nisin
A caused a slight delay in growth relative to the non nisin-
containing control at the concentration of peptide used (0.2 µM;
0.6 µg/ml) (Figure 2A). Identical concentrations of nisin I4V
resulted in a greatly extended lag time, highlighting its greater
potency as previously observed (Field et al., 2015b). Furthermore,
when combined with penicillin (0.8 µg/ml), the nisin I4V
+ penicillin combination appeared to completely inhibit the
growth of S. pseudintermedius DSM 21284. This impact was not
apparent for any other combination of nisin or nisin variant
(M21V) and penicillin or when any antimicrobial compound was
used alone (Figure 2A). Indeed, the benefits of employing I4V
were evident when combinations of nisin and nisin derivatives
with chloramphenicol (Figure 2B), vancomycin (Figure 2C),
and erythromycin (Figure 2D) were used in that the longest
lag in growth was observed for the nisin I4V and antibiotic
combination compared to all others tested.
Infections caused by antibiotic-resistant strains of S. aureus
have reached epidemic proportions globally. Indeed, the overall
burden of staphylococcal disease particularly that caused by
FIGURE 1 | Growth curve analysis of Staphylococcus aureus SA113 in the presence of nisin A (A), nisin V (V), and nisin I4V (I4V) peptides (0.937 µM;
3.0 µg/ml) and in combination with 1.5 µg/ml chloramphenicol (Cm), 5.0 µg/ml vancomycin (Van) and 0.005 µg/ml penicillin (Pen). The means and
standard deviations of three independent determinations are presented.
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FIGURE 2 | Growth curve analysis of S. pseudintermedius DSM21284 in the presence of nisin A (A), nisin V (V), and nisin I4V (I4V) peptides (0.292 µM;
0.932 µg/ml) and in combination with 0.8 µg/ml penicillin (Pen), 3.0 µg/ml chloramphenicol (Cm), 0.5 µg/ml vancomycin (Van), and 4.0 µg/ml
erythromycin (Ery). The means and standard deviations of three independent determinations are presented.
methicillin resistant S. aureus strains (MRSA), is increasing
in many countries in both healthcare and community settings
(Chambers and Deleo, 2009). Consequently, we wished to
explore the potential of nisin derivative/antibiotic combinations
to inhibit the methicillin resistant S. aureus ST528 (MRSA) strain
chosen as the representative clinical pathogen for combinatorial
experiments and growth curve analysis. While the derivatives
nisin V and I4V produced a slightly longer delay in growth than
the wild type nisin A peptide (0.2 µM), combinations of nisin and
the variants with chloramphenicol (2.5 µg/ml) and vancomycin
(0.2 µg/ml) did not produce any greater inhibitory effect than
when any of the compounds were used alone (Figures 3B,C).
Similarly, no additional inhibitory effect was observed when
penicillin (2.0 µg/ml) was utilized (data not shown) and this
trend was also observed when streptomycin (2.0 µg/ml) was
applied (Figure 3A).
Investigation of the Anti-Biofilm Activity
of Nisin and Antibiotic Combinations
In addition to specific antibiotic resistance, staphylococci
have non-specific mechanisms of resistance, of which biofilm
formation is undoubtedly the most important (Jain and Agarwal,
2009). Although a number of methods have been developed for
cultivation and quantification of biofilms (Stepanovic´ et al., 2007)
including the tube test, radiolabeling, microscopy, and Congo
red agar plate test, the microtiter plate method remains among
the most frequently used assays for investigation of biofilms
(O’Toole, 2011). Here, we employed the rapid colorimetric
XTT assay to study pre-formed biofilms of S. aureus SA113
and S. pseudintermedius DSM21284 since this method provides
evidence relating to the viability of the remaining biofilm
cells following combinatorial peptide/antibiotic treatment which
cannot be established via crystal violet staining and because it
allows the study of intact biofilms.
In view of the enhanced inhibitory effect of nisin, nisin V, and
nisin I4V derivatives + chloramphenicol combinations against
vegetative cells of S. aureus SA113 (Figure 1A), we sought to
determine if these combinations could also be effective against
pre-formed biofilms. Following preliminary experiments with
1X, 2X, 4X, and 6X MIC of nisin and chloramphenicol alone
(data not shown), biofilms of S. aureus SA113 formed on a
96-well plate were incubated with nisin and nisin derivative
peptides at a concentration of 6X MIC (15 µM; 50.2 µg/ml),
chloramphenicol at 2X MIC (8 µg/ml) and combinations thereof
for 24 h. The results revealed that while chloramphenicol alone
had no significant effect (p = 0.2156) compared to the untreated
control, nisin, and nisin variants as well as the peptide/antibiotic
combinations did result in a significant decrease in biofilm
viability compared to the untreated control (Figure 4A). Notably,
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the metabolic activity of biofilms treated with nisin V +
chloramphenicol and I4V + chloramphenicol combinations was
significantly diminished (p= 0.0002 and p= 0.0005, respectively)
compared to the nisin A + chloramphenicol treatment. Indeed,
this result was in agreement with the observed enhanced effect
with similar peptide/antibiotic combinations in growth curve
analysis against vegetative cells of S. aureus SA113 (Figure 1A).
For nisin treatment alone of pre-formed S. pseudintermedius
DSM21284 biofilms, a concentration of 4X MIC (1.25µM;
4.19µg/ml) was chosen since previous studies had established
that no significant difference was observed in biofilm mass of
S. pseudintermedius DSM21284 treated with 4X MIC of I4V
peptide compared to the wild-type nisin A treated biofilms
(Field et al., 2015b). Preliminary treatments of established
S. pseudintermedius DSM21284 biofilms with 1/2X (4 µg/ml),
1X (8 µg/ml), and 2X MIC (16 µg/ml) of chloramphenicol
concentrations revealed that only at 2X MIC was a minor
reduction in the biofilm viability observed as determined
by XTT assay (data not shown). Thus, for combinatorial
experiments, nisin A and nisin derivatives were used alone
at 4X MIC, chloramphenicol at 1X MIC and the relevant
combinations thereof. Following addition of XTT and optical
density readings at 492 nm (OD492), no substantial change
in biofilm viability was observed following 24 h treatment
with nisin A and nisin derivatives alone, chloramphenicol
alone, or nisin/chloramphenicol combinations (Figure 4) with
the exception of nisin I4V + chloramphenicol, where biofilm
viability was virtually undetectable compared to the XTT
(negative) control (Figure 4B). To assess the visual impact
of nisin + antibiotic treatments, the experiment was repeated
to enable visualization of the treated biofilms using confocal
microscopy in conjunction with the BacLight LIVE/DEAD
staining kit which facilitates differentiation between active
and dead cells (Figure 5). The results revealed that the
lower fluorescence signalsobserved for the nisin I4V +
chloramphenicol treated biofilm compared to that for all other
FIGURE 3 | Growth curve analysis of S. aureus ST528 (MRSA) in the presence of nisin A (A), nisin V (V), and nisin I4V (I4V) peptides (0.2 µM) and in
combination with 10 µg/ml streptomycin (Str), 2.5 µg/ml chloramphenicol (Cm) and 0.2 µg/ml vancomycin (Van). The means and standard deviations of
three independent determinations are presented.
FIGURE 4 | Viability of biofilms of (A) S. aureus SA113 untreated, and treated with 6X MIC (15µM) of nisin A, nisin V (M21V), and nisin I4V and peptides
alone and in combination with 2X MIC chloramphenicol for 24 h and (B) S. pseudintermedius DSM 21284 treated with 4X MIC (1.25 µM) of nisin A,
nisin V (M21V), and nisin I4V peptides alone and in combination with 1X MIC chloramphenicol for 24 h as evaluated by XTT
(2,3-bis[2-methyloxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-carboxanilide) assay measured using a microtiter plate reader. The means and standard
deviations of triplicate determinations are presented. Asterisks indicate statistically significant differences (Student’s t-test) between peptide and antibiotic
combinations used at similar concentration (∗∗∗p < 0.001).
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FIGURE 5 | Live/dead staining confocal images of S. pseudintermedius DSM21284 biofilms (A) untreated, (B) chloramphenicol (Cm) 1X MIC (8 µg/ml),
(C) nisin A 4X MIC (1.25 µM), (D) Nisin V (M21V) 4X MIC (1.25 µM), (E) nisin I4V 4X MIC (1.25 µM), (F) nisin A + Cm, (G) nisin V + Cm, and (H) nisin
I4V + Cm.
treatments was not due to less metabolic activity attributable to
cell death alone, but also as a result of the reduction in biofilm
density following treatment (Figure 5H).
DISCUSSION
Staphylococci are commensal bacteria living on the epithelial
surfaces of humans and other mammals, and many including
S. aureus, S. epidermidis, and S. pseudintermedius, can cause
severe disease when they breach the epithelial barrier.
Ominously, antibiotic resistance is widespread in staphylococci,
significantly complicating treatment. Moreover, many
staphylococci form biofilms, complex structures that confer
increased resistance to chemotherapies and host defense
mechanisms, making infections difficult to eradicate. Recently,
the dramatic rise in antibiotic-resistance has stimulated renewed
efforts to identify, develop or redesign existing antimicrobial
agents active against these multi-resistant bacteria. Due to their
many unique properties, the lantibiotics have become the focus
of many biomedical and pharmaceutical research groups due
to their demonstrable high potency in vitro, multiple modes of
action and ability to destroy target cells rapidly (Cotter et al.,
2005a; Cavera et al., 2015a). Furthermore, because lantibiotics
such as nisin are produced as gene-encoded pre-peptides, they are
infinitely more suited than classical antibiotics to bioengineering
which could lead to the generation of a new source of potent
antimicrobials. Here, we set out to examine for the first time, the
ability of nisin and two enhanced bioengineered nisin derivatives
(nisin V and nisin I4V) in conjunction with a selection of
conventional antibiotics to control a range of Staphylococcus sp,
including human and veterinary pathogens, with the ultimate
aim of identifying superior anti-biofilm combinations. Indeed,
following MIC determinations and growth curve analysis in
the presence of nisin, nisin V, nisin I4V and selected antibiotic
combinations, enhanced inhibitory relationships between nisin
+ penicillin and nisin + chloramphenicol were observed,
but were antibiotic and strain dependent. No synergy was
observed for nisin + vancomycin combinations against any
of the strains tested. Previous studies have confirmed that
synergistic interactions between nisin and vancomycin against
MSSA and MRSA can vary widely (Dosler and Gerceker, 2011,
2012). Similarly, nisin + penicillin proved highly efficacious in
combination against S. pseudintermedius DSM21284 but not
S. aureus SA113 or MRSA (ST528), while chloramphenicol and
nisin combinations proved effective against S. pseudintermedius
and S. aureus SA113 but not S. aureus ST528 (MRSA). While
this is in agreement with previous reports revealing that nisin
and chloramphenicol antagonized each other and did not inhibit
the growth of 18 of the 19 MRSA strains tested (Brumfitt et al.,
2002), studies involving E. faecalis have demonstrated synergism
between nisin and chloramphenicol and indeed nisin and
penicillin (Tong et al., 2014). Importantly, this synergism also
extended to biofilms since confocal laser scanning microscopy
revealed that penicillin, ciprofloxacin, and chloramphenicol all
displayed stronger anti-biofilm actions in combination with
nisin than when these antibiotics were administered alone
(Tong et al., 2014). Notably, from the point of view of this
study, the derivatives nisin V and I4V both displayed greater
potency than nisin A when combined with penicillin and
chloramphenicol against S. aureus SA113 biofilms. Similarly,
nisin I4V + chloramphenicol proved to be the most effective
combination against preformed biofilms of S. pseudintermedius
DSM21284, not only in killing biofilm-associated cells but also
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in reducing the density of established biofilm (as observed
by a decrease in both green and red fluorescence signals).
These findings are significant and represent the first report of
bioengineered nisin peptides that are improved in combination
with specific antibiotics against planktonic or biofilm-associated
cells. The findings also further highlight the merits of employing
antibiotic combination strategies to enhance the efficacy of
available antibiotics, and ultimately, restore sensitivity and
reduce their minimum effective dose. These approaches appear
particularly promising for combinations of antimicrobials that
target different sites. Surprisingly, many studies have shown
that the penetration of antibiotics is not lacking in bacterial
biofilms. For example, vancomycin diffuses rapidly in biofilms
of S. epidermidis (Darouiche et al., 1994) and MRSA (Okuda
et al., 2013), but exhibits diminished antimicrobial efficacy on
bacteria in the biofilm environment. Critically, a number of
studies have shown that nisin is bactericidal as a result of
its ability to access even the deepest part of a biofilm matrix
(Davison et al., 2010; Okuda et al., 2013). Notably, the results
generated in this study suggest that specific therapies such
as bioengineered nisin peptide and antibiotic combinations
may be more efficacious against biofilms, and permit the
dose of the individual antimicrobials to be reduced and
consequently counter the development of drug-resistance in
bacteria. Additionally, the opportunity also exists to combine
nisin V and nisin I4V with other antimicrobial agents,
including naturally derived compounds including essential oils,
diterpenoids and thiazolidinone derivatives that affect biofilms
via non-microbiocidal mechanisms, but instead target specific
molecular pathways that regulate biofilm formation (Buommino
et al., 2014). Furthermore, given that resistance to antimicrobials
that target lipid II does not develop easily, combinations of lipid
II-targeting compounds may also be indispensable given that
it is becoming more and more evident that this essential wall
precursor plays a key role in organization of the membrane
(Scheffers and Tol, 2015).
From a commercial perspective, it is notable that neither nisin
A nor any other lantibiotic is currently employed commercially
as a clinical antimicrobial. Its potential with respect to clinical
applications is strengthened by laboratory based experiments
highlighting its activity against human pathogens, including
multi-drug resistant strains (Cotter et al., 2005a; Piper et al.,
2009a). Nisin or nisin variants could be applied in the form
of a topical therapy as a treatment for generalized bacterial
skin infections, and/or used as an adjunct to systemic therapy.
Alternatively, nisin could also be an effective inhibitor of biofilms
which form on in-dwelling devices or hospital equipment.
Notably, although S. epidermidis and S. aureus have been
shown to form in vivo biofilms on implanted devices and
are the most common pathogens associated with infections of
surgical implants and other prosthetic devices, the ability to
form a biofilm is only recently gaining attention in the case of
S. pseudintermedius (Singh et al., 2013).
Although a number of drawbacks pertaining to lantibiotic
peptides and their suitability for use as therapeutics are apparent,
including low bioavailability and high cost of production, these
obstacles may be overcome since a broad range of technologies
have been developed for the engineering of lantibiotics. Indeed,
the past decade has seen several bioengineering studies describe
the generation of peptide derivatives including nisin with
enhanced functionality in terms of specific activity, spectrum
of activity, solubility and/or temperature and pH stability
(Field et al., 2015a). Additionally, genetic systems are in
continuous development to increase yields of peptide that
may aid commercial viability (Kong and Lu, 2014). The
further application of these systems to enhance nisin and
other lantibiotics has the potential to lead to the development
of novel derivatives for therapeutic use and contribute to a
solution to antibiotic resistance across a broad range of bacterial
pathogens. In conclusion, we have demonstrated the superior
capacity of bioengineered nisin derivatives in combination with
classical antibiotics to bring about the destruction of established
staphylococcal biofilms of S. aureus and S. pseudintermedius,
which may have future applications for the elimination of
problematic biofilms and associated infections.
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